Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

257.78

-1.58 (0.61%)

as of Oct 21, 2026, 8:00:00 pm Market Closed.

697 watching

DON'T BUY

Seening a little more strength on the pharmaceutical side. He would still prefer to go to the generics.

BUY

Finds the valuation a little bit high relative to the growth rate. A strong brand name. You can buy this and put it away for a number of years. Very low risk.

WAIT

Sold off when it broke a technical signal in the early spring. Starting to look interesting at this price. Has a lot of free cash flow. It's only 50% pharmaceutical with the rest being consumer products. All the big pharmas are under pressure because of some hearings in the next few weeks.

BUY

This has not been a great environment in the last few years for drug stocks, but J&J has been an exception. A diversified medical company with all kinds of businesses. Has been the best performing drug stock and thinks it will continue to be.

TRADE

The only drug company they own and it is for the medical devices and for the consumer products rather than the pharmaceuticals.

TRADE

Has the best fundamentals of all the drug stocks. Drug sector has come under a number of significant pressures.

BUY

A great company. Feels the US$ will drop so there is a modest exchange risk.

BUY

May be considered boring, but the stability in terms of earnings is going to work well as a theme in the sector.

BUY

Widely diversified product line and not like normal pharmaceutical companies.

TOP PICK

A great business. Low valuation.

TOP PICK

Good ballast for portfolios. Cheap valuation.

TOP PICK

2% yield. Didn't do much over the last year but is starting to recover with different products. On a valuation basis compared to their peers, they are at a much deeper discount. A safe investment.

TOP PICK

Pays a little over 2% dividend. A multitude of products. Terrific track record of making money. A safe place to be in uncertain times.

TOP PICK

With the feds tightening and profit growths slowing, the market is going ahead for higher quality stocks. A well-run company and is not expensive.

BUY

Likes the longer-term outlook for pharmaceuticals. Historically, they have performed relatively well when interest rates are going up.

Showing 571 to 585 of 630 entries

Most Recent Experts

Gordon Reid

GoodReid Investment Counsel

Keith Richards

ValueTrend Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Bruce Campbell (2)

Stone Castle Investment Management Inc.

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)